Amgen Inc.

AMGN-Q

NASDAQ:AMGN

258.60
1.50 (0.58%)
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm.
More at Wikipedia

Analysis and Opinions about AMGN-Q

Signal
Opinion
Expert
BUY
BUY
November 29, 2016

Great company. A cheap stock, trading at 11X earnings. Good dividend yield of about 2.75 %. Thinks they are going to do very well going into 2017. Have some great products coming out. They have a pristine balance sheet.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
November 29, 2016

Great company. A cheap stock, trading at 11X earnings. Good dividend yield of about 2.75 %. Thinks they are going to do very well going into 2017. Have some great products coming out. They have a pristine balance sheet.

HOLD
HOLD
November 22, 2016

(Market Call Minute.) Many people thought the Biotech sector would behave better if Trump got elected. It has had a lift, but it remains to be seen if it can be followed through.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
November 22, 2016

(Market Call Minute.) Many people thought the Biotech sector would behave better if Trump got elected. It has had a lift, but it remains to be seen if it can be followed through.

WATCH
WATCH
October 28, 2016

He sold all his biotech stocks in late August. He likes them from a seasonal perspective. He likes the whole sector long term. It is in a secular bull market. Biotechs are very volatile.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
October 28, 2016

He sold all his biotech stocks in late August. He likes them from a seasonal perspective. He likes the whole sector long term. It is in a secular bull market. Biotechs are very volatile.

BUY
BUY
September 13, 2016

A great company and one of the stronger performers in its category. 2.5% dividend yield. Growing earnings at about 10%. They have very strong franchises. You could also buy a basket of the big biotech companies through the Spdr S&P Biotech (XBI-N) ETF. The only difficulty is that to move the needle on a $125 billion company is that they have to make a big acquisition, and there are not so many out there right now.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
September 13, 2016

A great company and one of the stronger performers in its category. 2.5% dividend yield. Growing earnings at about 10%. They have very strong franchises. You could also buy a basket of the big biotech companies through the Spdr S&P Biotech (XBI-N) ETF. The only difficulty is that to move the needle on a $125 billion company is that they have to make a big acquisition, and there are not so many out there right now.

WAIT
WAIT
August 26, 2016

(Market Call Minute.) He likes the biotech and the healthcare space, but there is some rhetoric coming out of the US in terms of politics. Keep an eye on that before buying a name like this.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
August 26, 2016

(Market Call Minute.) He likes the biotech and the healthcare space, but there is some rhetoric coming out of the US in terms of politics. Keep an eye on that before buying a name like this.

BUY
BUY
June 23, 2016

He likes healthcare. His model price is $163.61, an upside of 9% from the current price of $152. A year from now he feels it is worth $179. 2.7% dividend yield.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
June 23, 2016

He likes healthcare. His model price is $163.61, an upside of 9% from the current price of $152. A year from now he feels it is worth $179. 2.7% dividend yield.

COMMENT
COMMENT
June 22, 2016

Amgen (AMGN-Q), Celgene (CELG-Q) or Biogen (BIIB-Q)? These are 3 great companies. His preference would be this one, which is the leader in the space and the dominant player.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
June 22, 2016

Amgen (AMGN-Q), Celgene (CELG-Q) or Biogen (BIIB-Q)? These are 3 great companies. His preference would be this one, which is the leader in the space and the dominant player.

TOP PICK
TOP PICK
June 22, 2016

He owns 3 biotech companies in his portfolio, and he wants to own best in breed. In this latest correction in the biotech space, if you are looking to have exposure but big deep pipelines, good balance sheet, consistency and the ability to abstract revenue out of the drugs, this would be the one. Dividend yield of 2.66%.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
June 22, 2016

He owns 3 biotech companies in his portfolio, and he wants to own best in breed. In this latest correction in the biotech space, if you are looking to have exposure but big deep pipelines, good balance sheet, consistency and the ability to abstract revenue out of the drugs, this would be the one. Dividend yield of 2.66%.

BUY
BUY
June 16, 2016

Going into a presidential cycle, healthcare is the easiest target in the world. Drug prices in the US, unlike Canada, are incredibly high. Every major drug company is there, because they can charge whatever they like for drugs. This is why a lot of these types of stocks have gone down. He likes this one a lot, and has bought more at these levels. They have a great pipeline, it is not expensive and pays a great dividend.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
June 16, 2016

Going into a presidential cycle, healthcare is the easiest target in the world. Drug prices in the US, unlike Canada, are incredibly high. Every major drug company is there, because they can charge whatever they like for drugs. This is why a lot of these types of stocks have gone down. He likes this one a lot, and has bought more at these levels. They have a great pipeline, it is not expensive and pays a great dividend.

COMMENT
COMMENT
June 7, 2016

The largest biotech company globally. It has 14 drugs that are greater than $400 million in revenue. Has about $32 billion in cash against $25 billion in debt. Some of the concerns are around their pipeline and some of the drugs that will come off patent. It has been giving a 25% bump in dividends every year. Balance sheet and growth are excellent, and you are getting great dividend increases every year.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
June 7, 2016

The largest biotech company globally. It has 14 drugs that are greater than $400 million in revenue. Has about $32 billion in cash against $25 billion in debt. Some of the concerns are around their pipeline and some of the drugs that will come off patent. It has been giving a 25% bump in dividends every year. Balance sheet and growth are excellent, and you are getting great dividend increases every year.

BUY
BUY
May 9, 2016

It has an elevated horizontal narrow range after a long uptrend. It keeps retesting the highs. It means to him that the buyers were not hesitant, that they will pay top prices. This is bullish and it should break through.

Show full opinionHide full opinion

It has an elevated horizontal narrow range after a long uptrend. It keeps retesting the highs. It means to him that the buyers were not hesitant, that they will pay top prices. This is bullish and it should break through.

COMMENT
COMMENT
May 3, 2016

Right now the drugs are a fashion, and that is one thing that makes them interesting. Thinks this market is in a big rotational spin, and right now they are under attack because politicians are trying to get elected. If you are patient, he thinks this will be fine. It is well-run and has some good products. Expect there will be a lot more M&A activity in the drug space again.

Show full opinionHide full opinion

Right now the drugs are a fashion, and that is one thing that makes them interesting. Thinks this market is in a big rotational spin, and right now they are under attack because politicians are trying to get elected. If you are patient, he thinks this will be fine. It is well-run and has some good products. Expect there will be a lot more M&A activity in the drug space again.

PAST TOP PICK
PAST TOP PICK
March 24, 2016

(A Top Pick April 16/15. Down 8.57%.) A large biotech company. Pays a dividend has some great products. He continues to like it. They execute very well. To him it is really a pharmaceutical company. If you Buy at this time, you will do very well over the next couple of years. Wait until November to see how the political situation goes in the US.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
March 24, 2016

(A Top Pick April 16/15. Down 8.57%.) A large biotech company. Pays a dividend has some great products. He continues to like it. They execute very well. To him it is really a pharmaceutical company. If you Buy at this time, you will do very well over the next couple of years. Wait until November to see how the political situation goes in the US.

WEAK BUY
WEAK BUY
February 2, 2016

A really solid biotech company. Well diversified with a number of products. (See Past Top Picks.)

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
February 2, 2016

A really solid biotech company. Well diversified with a number of products. (See Past Top Picks.)

PAST TOP PICK
PAST TOP PICK
November 9, 2015

(A Top Pick Oct 30/14. Up 0.64%.) A great company and he still likes it. Volatile, so you have to have a bit of a stomach going forward. Have some great things in the pipeline and their present drugs are very good.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
November 9, 2015

(A Top Pick Oct 30/14. Up 0.64%.) A great company and he still likes it. Volatile, so you have to have a bit of a stomach going forward. Have some great things in the pipeline and their present drugs are very good.

Showing 31 to 45 of 105 entries